Association of Anti-Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 30998826.
- Also identified by DOI 10.1001/jamaoncol.2019.0046 and PMC identifier 6567826.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This cohort study of patients with advanced melanoma treated with anti–programmed cell death 1 with or without ipilimumab assessed whether cutaneous toxic effects were associated with superior clinical outcomes.
Medical subject headings
- Antineoplastic Agents, Immunological
- Melanoma
- Programmed Cell Death 1 Receptor
- Skin Neoplasms